Provided by: Viral Hepatitis Grand Rounds from the Perelman School of Medicine at the University of Pennsylvania Academic Year 2014-2015 “Developing Synthetic DNA Immune Therapeutic Approaches for Chronic Infectious Agents” March 4, 2015 12:00 PM (EDT) - 1:00 PM (EDT) BRB II/III Auditorium David B. Weiner, PhD Professor, Department of Pathology and Laboratory Medicine Chair, Gene Therapy and Vaccine Program, CAMB Co-Leader Tumor Virology Program, Abramson Cancer Program University of Pennsylvania, Perelman School of Medicine Philadelphia, Pennsylvania Target Audience This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses, nurse practitioners, physician assistants and allied health professionals in the medical specialties of infectious disease, hepatology, gastroenterology, and internal medicine Educational Objectives After completing this activity, participants should be able to: Demonstrate increased understanding of the epidemiology of and risk factors for viral hepatitis. Increase the rate of testing for viruses associated with hepatitis. Demonstrate improved knowledge, competence and clinical practice in terms of the current standards and guidelines for the management of patients with viral hepatitis. Demonstrate an improved understanding of the treatment of viral hepatitis in patient co-infected with HIV or other viral infections. Accreditation The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation of Credit The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgement of Commercial Support* Gilead Sciences Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., Jansen Therapeutics, Division of Janssen Products, LP, AbbVie Inc., Vertex Pharmaceuticals, Inc. For more information, please contact Richard Gordon 847-951-5318 rgorgdon@viraled.com Check your CME online at www.penncmeonline.com Disclosure of Relevant Financial Relationships and Unapproved Uses of Products It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. For this purpose we consider relationships of the person involved in the CME activity to include financial relationships of a spouse or partner. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations. The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, Director of CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity. The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity: PLANNING COMMITTEE MEMBER NAME BRIAN BOYLE MILA KOSTIC OLIVER FULTZ MICHAEL SCHOEN, PHD RICK GORDON The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity. PLANNING COMMITTEE MEMBER NAME DAVID KAPLAN, MD IAN FRANK, MD K. RAJENDER REDDY, MD MARK SULKOWSKI, MD NAME OF COMMERCIAL INTEREST BAYER PHARMACEUTICALS GILEAD, VIIV JANSSEN GLAXOSMITH KLINE, BAVARIAN NORDIC JANSSEN, MERCK, GENENTECH-ROCHE, GILEAD, BMS, ABBVIE JANSSEN, MERCK, GILEAD, BMS, ABBVIE ABBVIE, BMS, GILEAD, MERCK, JANSSEN, BIPI ABBVIE, BMS, GILEAD, MERCK, JANSSEN, TOBIRA GILEAD RELATIONSHIP RESEARCH SUPPORT HONORARIUM CONSULTANT RESEARCH SUPPORT HONORARIUM RESEARCH SUPPORT RESEARCH SUPPORT SCIENTIFIC ADVISOR DSMB PRESENTER NAME DAVID B. WEINER, PHD NAME OF COMMERCIAL INTEREST RELATIONSHIP ROCHE SPEAKER/CONSULTANT SANOFI, MERCK SPEAKER INOVIO* CONSULTANT/SAB SERVICE *DR. WEINER HAS RECEIVED STOCK AND ROYALTIES UNDER THE UNIVERSITY OF PENNSYLVANIA PLAN DUE TO LICENSING OF SPECIFIC TECHNOLOGY TO INOVIO. HE HAS A MANAGEMENT PLAN IN PLACE AS PER UNIVERSITY OF PENNSYLVANIA COI POLICY. Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected PRESENTER NAME DAVID B. WEINER, PHD PRODUCT INVESTIGATIONAL AND/OR OFF-LABEL USE MY PRESENTATION WILL DISCUSS DNA VACCINE TECHNOLOGY WHICH IS BEING DEVELOPED BY INOVIO IN PART AS WELL AS OTHER COMPANIES. THE CLINICAL DEVELOPMENT OF DNA TECHNOLOGY IS ONE ASPECT OF THIS LECTURE.